Therapeutic antibodies are a new generation of pharmaceuticals which increasingly become more important. Diagnostics for these therapies are desirable, but currently not available. The aim was to develop an in-vitro procedure for the estimation of both the therapeutic antibody and the antigen in serum samples by use of a sandwich immunoassay.
Future
The Recovery-ELISA is an emerging technology with high potencial for development of antibody therapies and therapeutic monitoring in clinics. This new diagnostic method is a tool for optimization of antibody therapies. It could be also a powerful instrument e.g. for prevention of side effects.
Available Kits and Kits in Development: 
Result
The application of the Recovery-ELISA was studied on clinical serum samples of patients treated respectively with Omalizumab and Adalimumab. Fig. 2 
Method
We have investigated the influence of the therapeutic antibody on the calibration curve of a conventional sandwich assay. Using the example of an IgE-Sandwich-ELISA Fig. 1 Before treatment 4,3 ± 6 1 0 0 ± 0 0 ± 0 After 4 weeks treatment 4,2 ± 9 1,1 ± 0,9 7,6 ± 6,3 
